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Historical perspective of living donor liver transplantation
See Ching Chan, Sheung Tat Fan
 REVIEW
after transplantation. These three cases, though ended up 
in hospital mortality, established the technical feasibility 
of  liver transplantation in human[4]. Only four years later, 
long survivals were achieved in four DDLT recipients[5]. 
To become a reliable treatment modality for end-stage liver 
diseases of  a number of  etiologies, DDLT has taken two 
important steps: the clinical use of  calcineurin inhibitor - 
cyclosporine A[6] and improvement of  graft preservation 
techniques by hypothermic perfusion utilizing University 
of  Wisconsin solution[7].
Soon after DDLT had become a standard clinical 
practice, it outstripped the supply of  deceased donor liver 
grafts. The shortage of  pediatric deceased donor liver 
grafts was even more marked. To overcome size disparity 
of  the graft and the child recipient, reduced-size liver 
transplantation was devised by Bismuth in 1984[8]. Through 
extension of  this concept, split-graft liver transplantation 
was then developed by Pichlmayr in 1988[9]. This enables 
transplanting one more recipient and circumventing graft 
size discrepancy in one go. The fi rst series was reported by 
Broelsch in 1990[10].
BIRTH OF LIVING DONOR LIVER
TRANSPLANTATION
Experience gained from in-situ donor hepatectomy in 
reduced-size and split-graft DDLT paved the way for 
LDLT, an idea proposed by Smith as early as 1969[11]. 
When harvesting was performed on the living donor, much 
more technical ingenuity was required. The fi rst attempt 
was made by Raia[1] and fi rst success achieved by Strong 
of  Australia[12] in July 1989. Under stringent review and 
auspices of  the internal review board[13], the Chicago group 
led by Broelsch developed the first adult-to-child LDLT 
program[10]. Small series of  adult-to-child LLDT were then 
reported from the United States[14] and Europe[15].
The problem of  deceased donor liver graft shortage 
has been particularly severe in Asia[16]. In Japan, where 
deceased donor graft donation was non-existent[17] and 
liver surgery already well-developed, LDLT fl ourished[18,19]. 
For adult-to-adult LDLT (ALDLT), the left liver was used 
initially and was reported by the Shinshu group[20]. The 
left lobe used for adults was very often handicapped by 
the inadequate graft size. In 1993, Kyoto reported their 
improvisation of  using the right lobe in a case of  adult-to-
child LDLT for a 9-year old recipient. The intention in this 
particular case was to avoid precarious arterial anatomy of  
the donor’s left lobe[21]. The fi rst case of  right lobe ALDLT 
was performed at Queen Mary Hospital, the University 
of  Hong Kong on May 10th 1996. A priori, the right liver 
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Abstract
Living donor liver transplantation (LDLT) has gone 
through its formative years and established as a 
legitimate treatment when a deceased donor liver graft 
is not timely or simply not available at all. Nevertheless, 
LDLT is characterized by its technical complexity and 
ethical controversy. These are the consequences of a 
single organ having to serve two subjects, the donor 
and the recipient, instantaneously. The transplant 
community has a common ground on assuring donor 
safety while achieving predictable recipient success. With 
this background, a refl ection of the development of LDLT 
may be appropriate to direct future research and patient-
care efforts on this life-saving treatment alternative. 
© 2008 WJG. All rights reserved.
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INTRODUCTION
Living donor liver transplantation (LDLT) has been 
rapidly growing and evolving since its debut in 1989[1], 
while deceased donor liver transplantation (DDLT) had 
already been a standard procedure for a decade[2,3]. LDLT 
being the legitimate remedy for the refractory shortage of  
deceased donor liver grafts is characterized by its technical 
complexity and ethical controversies. 
In 1963, Starzl described in detail three cases of  DDLT. 
The fi rst recipient was a 3-year-old boy with biliary atresia 
and died from intra-operative hemorrhage. The other 
two recipients were adult males with primary liver cancer. 
Both succumbed to pulmonary embolism 7 and 22 d 
graft design included the middle hepatic vein (MHV). This 
was to address the problem of  small-for-size syndrome[22]. 
The fi rst series was reported shortly[23].
Donor right hepatectomy is one of  the most major 
surgical living donor procedures. Subjecting a donor who 
has no medical indication for surgery to a major surgical 
operation with attendant risks is an ethical challenge. It 
was viewed by the medical community and the society with 
caution and skepticism[24-26]. Such donor procedure could 
only be partially justified by the benefit on the recipient 
and exhaustion of  alternatives. This view is not universally 
accepted. Our common ground is the commitment to 
provide care of  the highest standard to the living liver 
donor. Efforts for the betterment of  care for the donors 
and yet not depriving them of  the chance of  saving or 
improving the life of  their beloved recipients should worth 
dedication and ingenuity of  the transplant community.
DONOR SAFETY AND WELLBEING
Donor safety is central to LDLT. As the application of  
LDLT extended from children to adults, and from using the 
left liver graft to the right liver graft, the dilemma between 
recipient success and donor risk came to the spotlight. The 
reported overall complication rate of  donors is around 
20%, but as high as 67% in one review[27]. A unifi ed system 
of  complication reporting[28] may narrow this range. Not 
only does the complication rate vary amongst different 
centers, the types of  complications reported also vary. 
The most common complications are wound infection, 
ileus, and bile leakage. With accumulation of  experience, 
donor morbidity could be lower than 20%. The majority of  
complications are of  Grade?and were wound infections. 
With careful attention to biliary anatomy and guidance 
from intraoperative cholangiography, biliary complications 
are avoidable[29]. While one donor mortality is too many 
for the transplant community, there are already 14 known 
donor deaths[30]. Donor right hepatectomy carries a 0.5% 
donor mortality rate[30]. Similarly, the causes of  donor 
mortality also vary[31]. A widely publicized case is a male 
donor in New York who succumbed to gas gangrene of  
Clostridium perfringens 3 d after donor right hepatectomy[32]. A 
hypertensive lady in Japan died from liver failure after right 
liver donation with a residual left liver with nonalcoholic 
steatohepatitis 28% of  the total liver volume[33]. Fatal 
pulmonary embolism also occurred in a left liver donor[34]. 
A donor mother with a history of  substance abuse also 
died from drug overdose 2 mo after donation to her 3 year-
old son[35]. In other words, achieving a five-year recipient 
survival of  80%, it takes one donor life to save 160 
recipients. Less tangible is the quality of  life changes of  the 
donor in comparison to the predonation state. The long-
term biological consequences of  donor hepatectomy are not 
fully known. Nevertheless, there are demonstrable drops 
in white cell count, platelet counts and elevation of  liver 
transaminases even two years after right liver donation[36]. 
Quantification of  such is mandatory in defining the field 
strength of  LDLT. Detail of  the holistic care of  living liver 
donors deserves elaboration in a separate synopsis. 
As agreed by the liver transplant community, living 
liver donors should be of  good health[30] and the donor 
operation performed by experienced centers[37]. There 
should be no compromise of  accepting potential donors 
with suboptimal physical and mental health. This is the 
only way to maintain or decrease donor mortality and 
morbidity.
RECIPIENT SHORT-TERM OUTCOMES
Graft size
Recipient survival is dependent on adequate graft size 
in relation to recipient body size[38]. Pathophysiology of  
the small-for-size graft and small-for-size syndrome is 
then defined[39]. Features include hepatocyte ballooning, 
steatosis, centri lobular necrosis, and parenchymal 
cholestasis. Pre-existing portal hypertension of  the 
recipient increases the size requirement of  graft[40].
Anecdotal success of  using a very small graft for 
ALDLT 25% of  the estimated standard liver weight[41] 
and even 20% with portosystemic shunting[42] had been 
reported. The paradigm shift from the left liver to the right 
liver enables adult recipients to undergo LDLT[43]. With 
technical maturity, 35% of  the estimated standard liver 
weight remains the minimum requirement of  a graft for 
predictable recipient success[44]. Portal hyperperfusion[45] 
and portal hypertension[46] are now conceived as possible 
mechanisms conducive to damage of  small-for-size grafts. 
A battery of  techniques for alleviation of  portal venous 
fl ow was described. This includes superior mesenteric vein 
to mesocaval shunt[47], hemiportocaval shunting[48], inflow 
modulation by splenic artery ligation[49]. With portosystemic 
shunting using a saphenous vein interpositional graft 
between the right portal vein and right hepatic vein stump, a 
left lobe 20% of  the estimated standard liver mass had been 
transplanted successfully in one patient[42]. Pharmacological 
manipulation is on the horizon as well[50].
More basic to these is the accurate assessment of  
standard liver volume of  the recipient and thus the 
minimum graft size requirements. There have been a 
number of  formulae developed from the west[51,52] and one 
from Japan[53]. A formula derived from Chinese and for 
application in Chinese which is also gender dependent has 
been developed and for validation[54].
Middle hepatic vein
Center to the controversy of  right lobe ALDLT is inclusion 
of  the MHV or otherwise. Deleterious effects of  no 
drainage to the segments 5 and 8 include severe venous 
congestion and necrosis of  these segments[55]. Surgical 
decision of  not including the MHV includes demonstration 
of  collaterals between segment 5 and 8 tributaries and the 
right hepatic vein[56]. Kyoto University devised an algorithm 
which includes the MHV when the graft is MHV dominant, 
or the graft to recipient weight ratio less than 1%, and 
in all cases, remnant left lobe larger than 35%[43]. Chang 
Gung Memorial Hospital includes the MHV when the 
graft to estimated standard liver volume is 50% or less, or 
when segment 5 and 8 hepatic veins are large and the right 
hepatic vein small[57]. Tokyo University ingeniously observed 
congestion of  segments 5 and 8 of  the graft after temporary 
clamping of  the right hepatic artery before determining 
venous interpositional grafting[58].
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We include the MHV in all right liver grafts for simplicity 
and familiarity of  the technique[59]. Irrespective of  the 
venous drainage pattern of  segment 4 of  the remnant left 
liver, the segment 4b hepatic vein is preserved. Utmost 
care is needed for its preservation when it drains into the 
MHV[60]. The outfl ow capacity is guaranteed by venoplasty 
on the back-table of  the MHV and right hepatic vein into 
a single cuff[61]. The venoplasty is further marked by a more 
expedient hepatic vein to inferior vena cava anastomosis and 
higher outfl ow capacity of  the right liver graft[62].
In summary, adequate graft size and quality, excellent 
venous outflow, and moderate portal inflow are keys to 
success of  ALDLT[63].
High urgency LDLT 
ALDLT under high urgency was impetus to development 
of  liver transplant in our center[23]. Early experience 
of  a number of  centers showed infer ior surgical 
outcomes of  ALDLT in the high urgency situation[64-66]. 
With accumulation of  experience and right liver graft 
incorporating the MHV, surgical outcomes of  ALDLT is 
not compromised[67]. We also showed that ALDLT improves 
the survival of  potential recipients[68]. The question of  
when a patient becomes too sick for liver transplantation 
is to be answered[69]. To justify ALDLT, good recipient 
outcome and acceptable donor morbidity, and voluntarism 
of  the donor are the least that could be expected. The Live 
Organ Donor Consensus Group has largely supported 
this viewpoint[70]. The Model for End-Stage Liver Disease 
score has been validated as a factor predictive of  recipient 
short-term survival in DDLT[71]. Data from ALDLT in 
North America[72] and Europe[73], however, do not support 
this view. Outside Asia, ALDLT is gradually considered a 
standard treatment for acute liver failure.
Biliary reconstruction
Biliary complication justifies itself  the Achilles' heel 
of  DDLT and is even more convincing in ALDLT[67]. 
Hepaticojejunostomy and duct-to-duct anastomosis 
have no substantial difference in the incidence of  biliary 
complications. Nonetheless, duct-to-duct anastomosis 
reduces the operating time and avoids contamination of  
the operation field, expedites return of  bowel functions, 
and avoids internal herniation of  bowel loops. It also allows 
subsequent intervention by endoscopic retrograde cholangio
pancreatography. In some centers, duct-to-duct anastomosis 
is stented to minimize the chance of  stensosis and leakage. 
Whether the stent plays a role in the postoperative period, or 
in facilitating anastomosis, or both, has not been validated. 
Furthermore, whether continuous or interrupted sutures 
makes a difference is unknown. A study on DDLT which 
showed no difference[74] may not be applicable to ALDLT. 
Randomized controlled trials of  recipients allocated to both 
arms may answer these questions.
RECIPIENT LONG-TERM OUTCOMES
Hepatocellular carcinoma
Early efforts of  transplanting patients with advanced 
unresectable primary liver cancers were tempered by 
invariable relapse of  malignancy[75]. Further work of  the 
same group established the correlation between poor 
prognosis and high pathological tumor-node-metastasis 
staging[76]. Vascular invasion by tumor is the single most 
important factor in treatment failure of  ALDLT for 
unresectable small hepatocellular carcinoma (HCC). Major 
vascular invasions though apparent for large tumors, 
may not be so for the small ones. Now called the Milan 
Criteria[77] and the University College of  San Francisco 
Criteria (UCSF)[78], the tumor size and number are used as 
surrogate parameters for likelihood of  vascular invasion. 
The Milan criteria are based on pretreatment imaging, 
whereas the UCSF criteria on liver explant histopathology. 
Accuracy of  preopera t ive imag ing in s t ag ing i s 
inadequate[79]. The tendency is toward underestimation 
of  tumor load. Even in studies with good image to 
histopathology correlation, underestimation is common. 
Tumor grade[80] and tumor size[81,82] are predictors of  
vascular invasion. Tumor size itself  is also a predictor of  
tumor grade[81,82].
In our own series of  ALDLT for HCC, there is a 
tendency of  a higher recurrence rate compared with 
DDLT. It is postulated that the higher regeneration rate 
and reperfusion injury of  small grafts in ALDLT provides 
an environment favorable for HCC cell implantation and 
growth in the graft[83]. It is also possible that in ALDLT, 
for preservation of  the inferior vena cava, more liver 
manipulation is required leading to tumor compression 
and cancer cell dissemination. However, it is not unlikely 
that patients who have received DDLT are the self-
selected patients because only candidates with slowly 
growing HCC who could wait for deceased donor liver 
grafts could receive the transplantation as the cancer cells 
are less aggressive. In fact, fast-tracking ALDLT for HCC 
had a higher recurrence rate[84]. Further studies on patient 
selection criteria and innovation of  surgical technique are 
required to improve the long-term outcome of  ALDLT 
for HCC. A recent series from Korea, nonetheless, has 
comparable results as DDLT[85]. 
In a series of  316 recipients with HCC who underwent 
ALDLT in Japan, the patient and recurrence-free survival 
rates were signifi cantly worse if  the Milan's criteria were 
not met. However, within this series, 171 (54.1%) of  
the recipients did not fulfi ll the Milan's criteria, and 176 
were staged ?a. The alpha-fetoprotein level, tumor 
size, vascular invasion, and bilobar distribution were 
independent risk factors for HCC recurrence. The grade 
of  histological differentiation of  HCC showed close 
correlation with tumor characteristics and recurrence. 
Mult i focal HCC verif ied by histopatholog y after 
transplantation with no recurrence was reported[86]. A 
policy of  extended indication beyond the Milan and UCSF 
criteria is being validated[87].
The fi rst use of  sirolimus in liver transplantation was 
in patients with liver cancer, using the reported antitumor 
effects of  the drug[88]. Subsequent work has shown effi cacy 
of  the drug in the inhibition of  hepatocellular tumor cell 
lines[89,90]. Recipients transplanted for HCC and received 
sirolimus and low dose tacrolimus survived longer[91]. 
Sequelae of long-term immunosuppression
Calcineurin inhibitors greatly improve graft and recipient 
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survivals. The lowest permissible serum drug level is 
employed to minimize the side effects. Nonetheless, 
two undesirable results still occur in recipients, i.e. renal 
impairment and tendency toward diabetes. A trend toward 
steroid-sparing immunosuppression seems workable[92]. 
The added benefi t of  the potential antineoplastic property 
of  sirolimus makes it very attractive for recipients with 
renal impairment transplanted for resectable HCC[93]. 
Prompted by development of  immune tolerance 
of  noncompliant l iver recipient after cessation of  
immunosuppressant therapy, weaning programs were 
incorporated into a long-term strategy of  liver transplant 
programs. Drug-free tolerance was observed more 
frequently in humans after transplantation of  the liver than 
of  any other organs. Clinical application of  cyclosporine[6] 
and then tacrolimus[94] dramatically prevented acute 
rejection of  transplanted organs. However, drug-free 
tolerance became rare with the dominance of  multiagent 
prophylactic immunosuppression[95].
Development of  tolerance to the graft obviates 
the use of  immunosuppressant with the side effects. 
The equivalence of  solid organ and bone marrow 
transplantation is substantiated by documentation of  
systemic microchimerism[96]. Liver cells were identifi ed in 
distant organs and host cells were also identifi ed in liver 
grafts. The mirror image of  solid organ and bone marrow 
transplantation envisioned by Starzl brings to light the 
practicality of  long-term donor specific tolerance. The 
liver as a privileged graft[97] is a constant source of  donor 
leukocyte, thus facilitates the process of  clonal exhaustion-
deletion especially in the early post-transplant phase under 
low immunosuppression pretransplant by antilymphocyte 
globulin. The concept of  prope tolerance is also proposed 
as a means to a similar condition at a lesser degree[98]. 
Utilizing a powerful lymphocyte-depleting antibody, 
Campath 1H, half-dose cyclosporine monotherapy 
became workable. During a window of  opportunity for 
immunologic engagement (WOFIE), it is hypothesized 
that there is engagement of  donor and recipient marrow 
cells. Not until the availability of  transgenic xenografts, 
effective and specific immunosuppression remains the 
practical way to graft maintenance. Nonetheless, continual 
assessment of  the risk of  chronic subclinical rejection is 
necessary[99].
CONCLUSION
At a minimum, recipient success is high and donor risk 
low. This brings donor and recipient issues into a close 
relationship. Conceptually, it would be inappropriate to 
accept a higher risk for the donor simply because of  the 
improvement of  recipient outcome. It is nonetheless 
our common goal to improve the standard of  recipient 
and donor operations. What the public should change is,
however, the better acceptance of  ALDLT in the face of  
better safety and success, while the effort to make more 
deceased donor grafts available is never be forgotten.
Now we have near perfect graft harvesting and 
implantation techniques. Excluding patients with 
prohibitive conditions, e.g. uncontrolled sepsis and poor 
cardiac conditions, the short-term success is predictable. 
We still require selecting patients with a low recurrence 
rate of  HCC and hepatitis C after transplantation. A 
lower biliary complication rate is welcome and could only 
be reduced by better preservation of  biliary vasculature 
on the donor and the recipient and careful anastomotic 
techniques.
Donor safety and recipient success are inseparable. 
While donor mortality is a reality, it is by lowering donor 
mortality and improving recipient survival the justifi cation 
of  LDLT becomes stronger.
Although the major interest of  the liver transplant 
community was in ALDLT in the last decade, the success 
of  ALDLT has been a result of  the ground works laid 
since the sixties. Key publications documenting the major 
achievements in liver transplantation leading to the ever 
improving results of  ALDLT are listed in chronological 
order in Table 1. 
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